Trial Profile
Ezetimibe + either atorvastatin or rosuvastatin versus atorvastatin or rosuvastatin (double dosing) in coronary artery disease patients with hyperlipidaemia refractory to standard therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2011
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Atorvastatin; Rosuvastatin
- Indications Coronary artery disease; Hyperlipidaemia
- Focus Pharmacodynamics; Therapeutic Use
- 04 May 2011 New trial record
- 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.